

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 14/05/2019

To  
The Manager  
Listing Department  
BSE Limited  
Bombay Stock Exchange,  
P. J. Towers, Dalal Street,  
Mumbai-400001.

Ref: Scrip code 956084 and ISIN INE988W07019

**Subject:** Submission under Regulation 52(1), 52(4), 52(5), 52 (7), 54 (2) and 56 (1)(d) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the subject matter, please find enclosed the following:

- i. The unaudited financial results of the Company for the half year ended 31<sup>st</sup> March, 2019 along with the Limited Review Report for that period issued by the Statutory Auditors SEBI (LODR), 2015.
- ii. The disclosure of the items as required under Regulation 52(4) of SEBI (LODR), 2015
- iii. A certificate signed by debenture trustee pursuant to Regulation 52(5) of SEBI (LODR), 2015.
- iv. A statement pursuant to Regulation 52(7) of SEBI (LODR), 2015.
- v. A disclosure under Regulation 54(2) of SEBI (LODR), 2015.
- vi. A certificate under Regulation 56 (1)(d) of SEBI (LODR), 2015.

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited

  
Ganeshprasad Gupta  
Company Secretary and  
Compliance Officer  
ACS No. 33925



# Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002, India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

To,

The Board of Directors,

M/S GENLINK PHARMA SOLUTIONS PRIVATE LIMITED,

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Mumbai

Dear Sir,

Re: Limited Review of Un-audited Financial Results for the Half Year ended 31<sup>st</sup> March , 2019 in respect of M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

## Introduction

We have reviewed the accompanying statement of unaudited financial results of M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED) for the half year ended 31<sup>st</sup> March , 2019 this statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a Report on these financial statements based on our review.

## Scope of Review

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Engagements to Review of Interim Financial Information performed issued by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



# Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

## Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e Ind AS prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For SHANKARLAL JAIN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Firm Registration No. 109901W/W100082

A handwritten signature in blue ink that reads 'Jain S.' with a horizontal line underneath.

SATISH JAIN

PARTNER

M. No. 048874

Place : MUMBAI

Dated : 14/05/19

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly Genlink Pharma Investments Private Limited)

CIN No : U74110MH2016PTC280765

Regd Off. Office No - 1704, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada Navi Mumbai, 400705, Maharashtra, India.

## Statement of Standalone Assets & Liabilities as on 31st March, 2019

INR

Sr. No.	PARTICULARS	As On 31-Mar-19 Unaudited	As On 31-Mar-18 Audited
<b>ASSETS</b>			
<b>Non Current Assets</b>			
1	Property, plant and Equipment	3,04,33,702	-
2	Investment Property	-	-
3	Intangible Assets	-	-
4	Financial assets (others)	-	-
5	Non current tax assets (Net)	-	-
6	Other Non current assets	24,89,95,479	24,89,95,479
<b>Total Non-current assets</b>		<b>27,94,29,181</b>	<b>24,89,95,479</b>
<b>Current Assets</b>			
1	Financial assets	-	-
2	Investments	-	-
3	Trade and other receivables	15,45,400	-
4	Cash and cash equivalents	6,601	23,387
5	Other financial assets	-	-
6	Other current assets	34,168	45,198
<b>Total Current assets</b>		<b>15,86,169</b>	<b>68,585</b>
<b>TOTAL ASSETS</b>		<b>28,10,15,350</b>	<b>24,90,64,064</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
1	Equity Share Capital	1,00,000	1,00,000
2	Other Equity	17,56,852	(27,69,928)
<b>Total Equity</b>		<b>18,56,852</b>	<b>(26,69,928)</b>
<b>Non-current Liabilities</b>			
1	Financial liabilities		
	(a) Long-term borrowings	27,29,48,634	25,01,50,000
	(b) Other Financial Liabilities	-	-
2	Long term Provision	-	-
3	Deferred Tax Liabilities (net)	-	-
4	Other Non-current Liabilities	-	-
<b>Total Non-current Liabilities</b>		<b>27,29,48,634</b>	<b>25,01,50,000</b>
<b>Current Liabilities</b>			
1	Financial Liabilities		
	(a) Trade and Other payables	-	-
	(b) Other financial liabilities	-	-
2	Short term provisions	10,54,000	50,000
3	Other current liabilities	51,55,864	15,33,992
<b>Total Current Liabilities</b>		<b>62,09,864</b>	<b>15,83,992</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>28,10,15,350</b>	<b>24,90,64,064</b>

For Genlink Pharma Solutions Private Limited

Anand Shah  
Director  
DIN: 00597145



Date: 14th May 2019  
Place: Navi Mumbai

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly Genlink Pharma Investments Private Limited)

CIN No : U74110MH2016PTC280765

Regd Off. Office No - 1704, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada Navi Mumbai, 400705, Maharashtra, India.

**Standalone Unaudited Financial Results for the Half Year and Year ended 31st March 2019**

INR

Sr. No.	Particulars	Half Year Ended		Year to date ended	Previous Year Ended
		31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18
		Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations				
(i)	Net Sales/Income from Operations (Net of excise duty)	48,70,000	-	78,70,000	-
(ii)	Other Income	-	-	-	-
	<b>Total Income from Operations</b>	<b>48,70,000</b>	<b>-</b>	<b>78,70,000</b>	<b>-</b>
2	Expenses				
(i)	Cost of Material Consumed	-	-	-	-
(ii)	Purchase of Stock in trade	-	-	-	-
(iii)	Change in Inventory of Finished Goods, Work In progress and Stock in trade	-	-	-	-
(iv)	Employee Benefits Expenses	-	-	-	-
(v)	Depreciation and Amortization Expenses	2,46,311	-	2,54,306	-
(vi)	Finance Cost	7,44,103	14,650	7,97,338	18,539
(vii)	Other Expenses	4,51,471	3,48,045	7,00,055	5,05,728
	<b>Total Expenses</b>	<b>14,41,885</b>	<b>3,62,695</b>	<b>17,51,699</b>	<b>5,24,267</b>
3	<b>Profit/(Loss) from operation before tax</b>	<b>34,28,115</b>	<b>(3,62,695)</b>	<b>61,18,301</b>	<b>(5,24,267)</b>
4	Tax Expenses	8,91,521	30,680	15,91,521	30,680
5	<b>Profit/(Loss) from ordinary activities for the period</b>	<b>25,36,594</b>	<b>(3,93,375)</b>	<b>45,26,780</b>	<b>(5,54,947)</b>
6	Other Comprehensive Income				
(i)	Items that will not be reclassified to profit or loss	-	-	-	-
(ii)	Items that will be reclassified to profit or loss	-	-	-	-
	<b>Total Comprehensive Income/(Loss) for the period</b>	<b>25,36,594</b>	<b>(3,93,375)</b>	<b>45,26,780</b>	<b>(5,54,947)</b>
7	Paid up Equity Share Capital of 10/- each	1,00,000	1,00,000	1,00,000	1,00,000
8	Earning per Share(not annualised)				
	Basic	253.66	-231.75	452.68	-55.49
	Diluted	253.66	-231.75	452.68	-55.49

For Genlink Pharma Solutions Private Limited

Anand Shah



Date: 14th May 2019

Place: Navi Mumbai

Anand Shah

Director

DIN: 00597145

WT 2

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

## DISCLOSURE UNDER REGULATION 52(4) OF SEBI (LODR), 2015

1. **Credit rating** - The Company's NCDs have been rated as "SMERA BB-" by SMERA Ratings Limited. There has been no change in the credit rating of the Company.
2. **Asset cover available** - The asset cover ratio works out to more than one time on the basis of valuation of the equity shares offered as security for the NCDs.
3. **Debt-equity ratio** - 147.74 times
4. **Previous due date for the payment of interest** - The Company has issued "Zero Coup" secured redeemable non-convertible debentures. Hence, no interest is required to be paid.
5. **Repayment of principal of non-convertible debt securities** - The secured redeemable non-convertible debentures are redeemable in full on September 27, 2021.
6. **Next due date for the payment of interest** - The Company has issued "Zero Coupon" secured redeemable non-convertible debentures. Hence no due date is applicable.
7. **Debt service coverage ratio** - 4.17 times
8. **Interest service coverage ratio** - 8.92 times
9. **Outstanding redeemable preference shares (quantity and value)** - The Company does not have any outstanding redeemable preference shares
10. **Capital redemption reserve/debenture redemption reserve** - Nil
11. **Net worth** - The net worth of the Company is Rs. - 18,56,852/-
12. **Net profit after tax**  
Net profit after tax of the Company is Rs 45,26,780/-
13. **Earnings per share**  
Earnings per share of the Company is Rs 452.68/-

For Genlink Pharma Solutions Private Limited



Ganeshprasad Gupta - Company Secretary and Compliance Officer

ACS No. 33925

Date: 14/05/2019

Office: 1704, 17<sup>th</sup> Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai - 400 705, India  
Ph: +91 22 6750 7000 Fax +91 22 6750 7070 Email [genlinkinfo@gmail.com](mailto:genlinkinfo@gmail.com) [www.genlinkpharma.com](http://www.genlinkpharma.com)  
CIN: U74110 MH 2016 PTC 280765



May 23, 2019

To  
Mr. Anand Shah,  
Compliance Officer,  
Genlink Pharma Solutions Private Limited  
1704, 17th Floor, Kesar Solitaire,  
Plot No. 5, Sector 19,  
Sanpada, Navi Mumbai - 400 705,  
Maharashtra, India.

**Subject:** Certificate of Debenture Trustee under Regulation 52(5) of SEBI (LODR), 2015 for the financial year ended 31<sup>st</sup> March 2019.

In compliance with the requirement of Chapter V, Regulation 52(4) and 52(5) of the Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 for Secured Redeemable Non-Convertible Debentures it is certified as under:

We, Vistra ITCL (India) Limited are acting as a Debenture Trustee for the debenture programme of Rated, Listed, Redeemable, Non-Convertible Debentures (NCDs) issue aggregating to Rs. 25 Crores of Genlink Pharma Solutions Private Limited (formerly known as Genlink Pharma Investments Private Limited), "the Company"

With reference to the above, we have received the following documents and noted its contents:

1. Audited financial results for the year ended 31<sup>st</sup> March, 2019 along with Audit report for the year ended 31<sup>st</sup> March, 2019.
2. Disclosure pursuant to Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the financial year ended 31<sup>st</sup> March, 2019.

This certificate has been signed and issued by us based on documents (mentioned above) submitted by you.

Thanking You.

Yours sincerely,  
For Vistra ITCL (India) Limited

Authorized signatory

Place: Mumbai


# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

## DISCLOSURE PURSUANT TO REGULATION 52 (7) OF THE SEBI (LODR), 2015

We hereby state that for the half year ended 31<sup>st</sup> March, 2019 there is no material deviation in the use of proceeds of Secured Redeemable Non-Convertible Debentures from the objects stated in the offer document.

For Genlink Pharma Solutions Private Limited



Ganeshprasad Gupta  
Company Secretary and  
Compliance Officer  
ACS No. 33925



# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

## DISCLOSURE UNDER REGULATION 54 OF SEBI (LODR), 2015

We hereby stated that the Company maintains as on half year ended 31<sup>st</sup> March, 2019 hundred percent asset cover sufficient to discharge the principal amount at all times for the non-convertible debt securities issued.

The details of extent and nature of security created and maintained with respect to its listed secured non-convertible redeemable debt securities are as follows:

1. 5,63,497 Equity shares of Enaltec Labs Pvt. Ltd. held by Genlink Pharma Solutions Private Limited.
2. 5,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Anand Shah.
3. 5,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Susheel Koul.

For Genlink Pharma Solutions Private Limited

  
Ganeshprasad Gupta  
Company Secretary and  
Compliance Officer  
ACS No. 33925



Date: 14/05/2019

**GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**  
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 15/05/2019

To  
The Manager  
Listing Department  
BSE Limited  
Bombay Stock Exchange,  
P. J. Towers, Dalal Street,  
Mumbai-400001

Ref: Scrip code 956084 and ISIN INE988W07019


**Subject:** Submission under Regulation 56(1) (d) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the subject matter, please find enclosed herewith the disclosure pursuant to the subject Regulation for the half year ended 31<sup>st</sup> March, 2019.

Please take the above information on your records.


For Genlink Pharma Solutions Private Limited

  
Ganeshprasad Gupta  
Company Secretary and  
Compliance Officer  
ACS No. 33925



# Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

## TO WHOMSOEVER IT MAY CONCERN

This is to certify that **GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**, (CIN U74110MH2016PTC280765) having its registered office at 1704, 17<sup>th</sup> Floor, Kesar Solitaire, Plot No 5, Sector 19, Sanpada, Navi Mumbai - 400705 has Asset Cover Ratio of **1.25 times** & Debt Equity Ratio of **147.47 times** as on quarter ended 31<sup>st</sup> March, 2019 based on the details and documents provided to us which is tabulated herein below:

Sr. No	Particulars	Unit	Amount (Rs)
a)	Non-Convertible Debentures (NCD) Value	Rs. Lacs	2,500/-
b)	Number of shares of Enaltec Labs Pvt. Ltd. Pledged	No.	5,75,343
c)	Valuation (As per Valuation Report dated 05 <sup>th</sup> January, 2017 Enaltec Labs Pvt Ltd. issued by CA Prashant Moliya and which is accepted as it is).	Rs./Share	544.52
d)	Value of Shares pledged ( Rs 544.52 * 5,75,343)	Rs. Lacs	3,133
e)	Security Cover (Rs Lacs 3,133/2500)	Ratio	1.25

Note: Shares include 11,846 shares pledged by Promoters (Mr. Anand Shah: 5,923 shares and Mr. Susheel Koul: 5,923 shares)

**Debt Equity Ratio** : Total Debt / Total Equity i.e Rs.27,38,26,818/18,56,852= **147.47 times**.

Since the Company has issued Zero Coupon Debentures, Debt Service Coverage Ratio and Interest Service Coverage Ratio are not applicable in the above mentioned NCD.

The above mentioned Company has utilized Debenture Subscription Receipts of Rs. 25,00,00,000/- (Rs Twenty Five Crores) for purchase of equity shares (5,63,497 equity shares) of Enaltec Labs Private Limited.



# Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

The above mentioned Company has not transferred any amount to Debenture Redemption Reserve as on period ended 31<sup>st</sup> March, 2019.

The above has been verified from the details and documents produced before us.



FOR SHANKARLAL JAIN & ASSOCIATES LLP,  
CHARTERED ACCOUNTANTS  
FIRM REG NO: - 109901W/W100082

Satish Jain  
PARTNER  
Membership No.: 048874  
UDIN : 19048874AAAABV6981

Place: Mumbai  
Date: 15.05.2019